Tideglusib

Generic Name
Tideglusib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H14N2O2S
CAS Number
865854-05-3
Unique Ingredient Identifier
Q747Y6TT42
Background

Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). Tideglusib is being developed by the Spanish pharmaceutic company Zeltia grou...

Indication

Tideglusib was initially formulated for the treatment of Alzheimer and progressive supranuclear palsy. The raising interest for the use of tideglusib comes from the significant upregulation of GSK-3 in the brain in patients with Alzheimer disease. Its function as a degradant of β-catenin, was also important, as it prevents the transcription of cell survival ...

Associated Conditions
-
Associated Therapies
-

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

First Posted Date
2023-12-18
Last Posted Date
2024-08-21
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
120
Registration Number
NCT06174220
Locations
🇨🇦

Saint Boniface Hospital, Winnipeg, Manitoba, Canada

🇨🇦

Hamilton General Hospital, Hamilton, Ontario, Canada

🇨🇦

Newmarket Electrophysiologist Research Group 'NERG', Newmarket, Ontario, Canada

and more 16 locations

Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2021-11-03
Last Posted Date
2023-06-02
Lead Sponsor
University Hospital, Geneva
Target Recruit Count
98
Registration Number
NCT05105958
Locations
🇨🇭

University Hospital Lausanne, Lausanne, Switzerland

🇨🇭

University Hospital Zurich, Zürich, Switzerland

🇨🇭

University Hospital Bern, Bern, Switzerland

and more 2 locations

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2021-08-13
Last Posted Date
2023-11-08
Lead Sponsor
AMO Pharma Limited
Target Recruit Count
76
Registration Number
NCT05004129
Locations
🇨🇦

Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

🇳🇿

New Zealand Clinical Research (NZCR), Auckland, New Zealand

🇺🇸

University of California, Los Angeles (UCLA), Los Angeles, California, United States

and more 11 locations

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2018-10-02
Last Posted Date
2023-09-08
Lead Sponsor
AMO Pharma Limited
Target Recruit Count
56
Registration Number
NCT03692312
Locations
🇦🇺

The Bright Alliance, Randwick, New South Wales, Australia

🇺🇸

University of Utah Hospital, Salt Lake City, Utah, United States

🇳🇿

New Zealand Clinical Research (NZCR), Auckland, New Zealand

and more 11 locations

Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2016-08-08
Last Posted Date
2018-12-27
Lead Sponsor
AMO Pharma Limited
Target Recruit Count
16
Registration Number
NCT02858908
Locations
🇬🇧

Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom

Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-10-27
Last Posted Date
2018-05-31
Lead Sponsor
Evdokia Anagnostou
Target Recruit Count
83
Registration Number
NCT02586935
Locations
🇨🇦

McMaster University, Offord Centre for Child Studies, Hamilton, Ontario, Canada

🇨🇦

University of Western Ontario, Lawson Health Research Institute, London, Ontario, Canada

🇨🇦

Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada

Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-05-09
Last Posted Date
2012-10-02
Lead Sponsor
Noscira SA
Target Recruit Count
306
Registration Number
NCT01350362

Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2010-01-14
Last Posted Date
2012-01-05
Lead Sponsor
Noscira SA
Target Recruit Count
146
Registration Number
NCT01049399
Locations
🇺🇸

University of Medicine and Dentistry, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

🇺🇸

The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States

🇪🇸

Fundació Ace, Barcelona, Spain

and more 21 locations
© Copyright 2024. All Rights Reserved by MedPath